Acute Myeloid Leukemia (AML) Models for Ex Vivo and In Vivo Study

Champions Oncology is a leader in patient-derived models for oncology drug development, with a variety of models of both solid and hematologic tumors available for drug development studies. Champions diverse hematologic malignancy bank includes over 30 models of Acute Myeloid Leukemia (AML), which include representatives of most AML subtypes, including models with a variety of molecular and phenotypic characteristics.

To model human AML in vivo, Champions uses primary patient samples, engrafted systemically for each human AML xenograft study to preserve the unique patient characteristics and to avoid genetic drift that may occur for passaged models. The result is a clinically-relevant in vivo model system that permits evaluation of novel therapeutic candidates.